Skip to main content

UPDATE: Agilent, MDS Proteomics to Collaborate on Protein Analysis Technology

NEW YORK, May 22 – Signaling its effort to expand into the burgeoning proteomics arena, Agilent Technologies said Tuesday it has agreed to partner with MDS Proteomics to develop laboratory technology for identifying and analyzing proteins more quickly. 

The joint effort will draw on Agilent’s expertise in separation science and liquid chromatography, and MDS Proteomics’ experience in mass spectrometry, bioinformatics, and the study of protein pathways.

“Right now getting [separations] technology configured for proteomics has tremendous benefit for our customers, “ said Doug Forsyth, a spokesman for Agilent. 

Forsyth said Agilent and MDS will combine existing technology such as liquid chromatography and mass spectrometry with bioinformatics solutions specifically tailored for proteomics to boost the throughput of protein analysis.

“Together we’ll identify bottlenecks, problems,” said Forsyth. “Agilent will come up with the equipment, and MDS will provide certain components” such as bioinformatics expertise.

From the collaboration, the two companies hope to sell equipment and laboratory technology to pharmaceutical, biotechnology, and other companies in engaged in proteomics research. Further financial details of the collaboration were not disclosed.  
The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.